Automated Susceptibility Testing.
MERLIN Diagnostika GmbH is a manufacturer of in-house developed diagnostics. Since the year 1990 with first launch of the MICRONAUT system, numerous products for automated microbial identification and antimicrobial susceptibility testing (AST) of clinical relevant bacteria and yeasts were developed and introduced on the market. The MICRONAUT products are applied in routine diagnostic laboratories in the field of human and veterinary medicine as well as in public or industrial research facilities.
Spend 3 minutes for deeper insights:
31.08.2022 | From a drug development perspective, cefiderocol is one of the most promising antibiotics, remaining active even when facing the most challenging carbapenem resistance mechanisms. To support antibiotic stewardship, clinical microbiologists are looking for reliable and accurate cefiderocol MIC testing in full compliance with EUCAST and CLSI standards. Bruker's UMIC® Cefiderocol and the associated iron-depleted Mueller Hinton broth offer an easy to implement solution and can conveniently be tested along with UMIC® Colistin to deliver trusted MIC results when it matters most.
For more information, please visit Bruker's website.
From January 2022 the MICRONAUT products have been transferred from MERLIN Gesellschaft fuer mikrobiologische Diagnostika mbH to Bruker Daltonics GmbH & Co. KG as legal manufacturer.
21.05.2019 | EUCAST warns against the use of gradient tests for vancomycin MIC determination, since this causes false susceptibility. EUCAST recommends products based on broth microdilution procedure as method of choice for vancomycin MIC determination to confirm vanB low-level resistance in Enterococcus faecalis and Enterococcus faecium. (ref. MIC-Strip Vancomycin/Teicoplanin).
More information about the difficulties in the EUCAST vancomycin susceptibiliy testing
11.09.2018 | The new two-test-plate MICRONAUT-S Carbapenemases Detection, which is based on broth microdilution procedure, provides phenotypic detection of clinically relevant carbapenemases (type A carbapenemases (e.g. KPC), metallo-β-lactamases, and OXA-48-like type D carbapenemases) in enterobacteria and Pseudomonas aeruginosa.
The layout of this special plate is available on request.
01.01.2017 | Last autumn, Dr. Esther Pfeil, Managing Director of MERLIN Diagnostika GmbH, took part in the election to the General Assembly of the chamber of commerce and industry Bonn / Rhein-Sieg. Since January 1st, 2017, she is representing the interests of the manufacturing industry in the Rhein-Sieg area for five years at the General Assembly. Dr. Pfeil decided to present herself as a candidate "since I am a managing director of an SME, I would like to take responsibility for the strengthening of small and medium-sized enterprises (SMEs) and their employees in our region. Subjects, of which I feel touched and which I would like to move forward, are the enhancement of market ability through innovation, the expansion of existing training and development programs to promote skilled workers, and the reconcilability of family and work."
28.11.2016 | Thanks to our microdilution procedure, EUCAST recommends our MICRONAUT products for Colistin testing!
More information about the difficulties in the EUCAST Colistin susceptibility testing
19.10.2016 | The plate MICRONAUT-UR, which is used in the bacteriological laboratory diagnostics for urology, is from now on available with an improved antibiotics spectrum. It has been enriched by the new antibiotic Mecillinam.
01.08.2016 | MERLIN Diagnostika is one of the winners of the first round in the key market competition LifeSciences.NRW: Referees voted for the joint research project "PathoSept", which is intended to save many lives by rapidly diagnosing threatening infections.
In the key market competition LifeSciences.NRW, 10 joint projects were selected from 51 contest entries, which will be funded with a total of 19.3 million euros.
"Winner is also our project 'PathoSept', with which we want to create a diagnostic complete system under the coordination of the Fraunhofer Institute for Applied Information Technology. It very quickly identifies pathogenic agents of life-threatening infections and simultaneously allows a quantitative determination of the antibiotic resistance profile. Based on these results, it can be initiated a targeted individual antibiotic therapy no later than nine hours", says Dr. Esther Pfeil, Managing Director of MERLIN Diagnostika.
In addition to the Fraunhofer Institute and MERLIN, the companies Carpegen GmbH, based in Münster, and Jüke Systemtechnik GmbH as well as the university clinics of Aachen and Bonn, belong to the network. The volume of this project is about 3.5 million euros.
Every year, more than 56,000 people die from sepsis in Germany, one of the most severe bacterial infections that can be even simply caused by a purulent tooth. Currently, the time between suspected diagnosis and targeted therapy can last up to five days, and infections with multiresistant pathogens can not be adequately treated. PathoSept is intended to open up the reliable diagnosis after nine hours, thus significantly reducing the high mortality rate, but above all the new generation and spread of multiresistant pathogens, as well as the intensive medical costs. With this an infection can be treated very early in the process and very specifically.
MERLIN has already made essential preparations for this project because we are specialized in the development, validation and marketing of various microbiological diagnostic systems for the qualitative and quantitative detection of microbial antibiotic resistance. MERLIN's diagnostic systems for quantitative susceptibility testing allow the determination of the minimum inhibitory concentration (MIC value) in accordance with the normative requirements. These systems are supplemented by phenotypic detection methods for the detection of clinically and epidemiologically relevant resistance mechanisms. MERLIN also has a great expertise in the handling of antimicrobial agents, which are meaningful in the validation of the manufacture, packaging, storage and application of antibiotic-containing diagnostics. "These are core competencies that make a decisive contribution to the successful implementation of the joint research project," emphasizes Dr. Esther Pfeil.
MERLIN is continuing the development of its products and processes, taking into account sustainability as well as environmental and economic aspects, with the aim of implementing the Antibiotic Stewardship for the rational use of the anti-infectives.
24.05.2016 | MICRONAUT-S MDR MRGN Screening, the updated MIC plate for the susceptibility testing of multi-resistant gramnegative bacteria (multidrug resistance phenotype), has been enriched with these new features:
MICRONAUT-S MDR MRGN Screening provides, based on the microdilution method, the phenotypic detection of clinically relevant resistance mechanisms in enterobacteria and nonfermenters, including the detection of cephalosporinases and carbapenemases.
16.03.2016 | The phenotypic detection of multiple ß-lactamases (multiple resistance determinants) in the single test system has been extended:
MICRONAUT-S β-Lactamases provides, based on the microdilution method, the phenotypic detection of clinically relevant cephalosporinases and carbapenemases in entero-bacteria and non-fermenters.
The layout of these special plates is available upon request.